PTEN and prostate carcinoma: Additionally, a study by Müller et al. showed that a small (4%) but clinically high relevant fraction of prostate cancers characterized by loss of pSer2448-mTOR expression, ERG fusion and PTEN deletion represents a molecularly distinct subgroup of tumors with aggressive and early recurrent features.